(:ATNX)

May 14, 2023 11:15 am ET
Athenex, Inc. Reaches Agreement With Lenders to Pursue Expedited Sales Process
Athenex, Inc., (NASDAQ: ATNX) (“Athenex” or the “Company”), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced...
May 01, 2023 01:00 pm ET
Quantum Leap Healthcare Collaborative Announces Result of Oral Paclitaxel in Combination with a PD-1 and Carboplatin from I-SPY2 TRIAL at ASCO
SAN FRANCISCO, May 1, 2023 /PRNewswire/ -- Quantum Leap Healthcare Collaborative (Quantum Leap) and Athenex, Inc. (Nasdaq: ATNX) will present the findings of the I-SPY 2 TRIAL evaluation of Athenex's oral paclitaxel plus encequidar in combination with GSK's dostarlimab in the neoadjuvant setting at this year's American Society of Clinical Oncology (ASCO) conference.
Mar 20, 2023 08:00 am ET
Athenex Provides Fourth Quarter and Full Year 2022 Financial Results and Business Update
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today provided a corporate and financial update...
Feb 14, 2023 08:00 am ET
Athenex Announces a Reverse Stock Split
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it will effect a 1-for-20...
Jan 03, 2023 08:00 am ET
Athenex Announces MHRA Decision on Oral Paclitaxel
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that its proprietary Oral...
Dec 20, 2022 09:49 am ET
Thinking about buying stock in Athenex, Camber Energy, Mullen Automotive, Iamgold, or United States Steel?
NEW YORK, Dec. 20, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ATNX, CEI, MULN, IAG, and X.
Dec 20, 2022 08:15 am ET
Athenex Announces Quantum Leap Healthcare Collaborative Reports Positive Trial Result of I-SPY2 Trial for Oral Paclitaxel in Combination with PD-1 and Carboplatin in Neoadjuvant Breast Cancer
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions announced that collaborators at the Quantum Leap...
Dec 16, 2022 08:00 am ET
Athenex Exits 503B Sterile Compounding Business
Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the exit of its 503B sterile...
Nov 22, 2022 10:30 am ET
Athenex Announces Positive Results of Special Stockholder Meeting
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the results of its special...
Nov 21, 2022 08:00 am ET
Athenex Announces Closing of the Sale of its China API Business
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the closing of the sale of its...
Nov 08, 2022 04:05 pm ET
Athenex to Participate in the 5th Annual Evercore ISI HealthCONx Conference
Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that management will participate in the...
Nov 03, 2022 07:05 am ET
Athenex Announces Receipt of Positive Nasdaq Listing Determination
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that a Nasdaq Hearings Panel...
Nov 03, 2022 07:00 am ET
Athenex Provides Third Quarter 2022 Financial Results and Business Update
Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today provided a corporate and financial update...
Oct 24, 2022 08:00 am ET
Athenex to Provide Corporate and Financial Update for the Third Quarter 2022 on November 3, 2022
Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a...
Oct 11, 2022 09:15 am ET
Athenex Files Definitive Proxy Statement for Special Stockholder Meeting
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it has filed a definitive...
Sep 06, 2022 11:00 am ET
Athenex to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that management will present at the...
Aug 11, 2022 04:21 am ET
Athenex, Inc. Announces Pricing of $30 Million Public Offering of Common Stock and Warrants
Athenex, Inc. (“Athenex”) (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the pricing of its...
Aug 10, 2022 04:01 pm ET
Athenex, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Warrants
Athenex, Inc. (“Athenex”) (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it intends to...
Jul 28, 2022 07:00 am ET
Athenex Provides Second Quarter 2022 Financial Results and Business Update
Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today provided a corporate and financial update...
Jul 25, 2022 10:00 am ET
Athenex Announces Publication of Data from Phase 3 Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients with Metastatic Breast Cancer in the Journal of Clinical On
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the publication of their...
Jul 21, 2022 01:00 pm ET
Athenex to Provide Corporate and Financial Update for the Second Quarter 2022 on July 28, 2022
Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a...
Jul 11, 2022 08:00 am ET
Athenex Announces Entry into Agreement to Sell its China API Business to TiHe Capital (Bejing) Co., Ltd.
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that Athenex and certain...
Jun 23, 2022 10:24 am ET
Athenex to Participate in Truist Securities Cell Therapy Symposium
Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that Daniel Lang, M.D., President,...
Jun 22, 2022 08:30 am ET
Athenex Announces Sale of Revenues from U.S. and European Royalty and Milestone Interests in Klisyri® (tirbanibulin) to Sagard Healthcare Partners and Oaktree
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the signing of a definitive...
Jun 08, 2022 08:00 am ET
Athenex Appoints Darrel P. Cohen, MD, PhD as Chief Medical Officer of Cell Therapy
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the appointment of Darrel P....
May 16, 2022 08:00 am ET
Athenex Announces Clinical Collaboration with Merck to Evaluate Oraxol plus KEYTRUDA® (pembrolizumab) in Patients with Non-Small Cell Lung Cancer (NSCLC)
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced a clinical trial collaboration...
May 10, 2022 07:00 am ET
Athenex Provides First Quarter 2022 Financial Results and Business Update
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today provided a corporate and financial update...
May 02, 2022 05:26 pm ET
Athenex, Texas Children’s Cancer Center, and the Center for Cell and Gene Therapy at Baylor College of Medicine to Present Phase 1 Clinical Data for KUR-501, an autologous GD2 CAR-NKT Cell Therapy for
Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will present at the...
Apr 29, 2022 08:00 am ET
Athenex to Provide Corporate and Financial Update for the First Quarter 2022 on May 10, 2022
Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a...
Apr 25, 2022 08:00 am ET
Athenex Presents Interim Data from Phase 1 ANCHOR Study of KUR-502 (Allogeneic CD19 CAR-NKT Cells) in Relapsed or Refractory Lymphoma and Leukemia at the 2022 Transplantation & Cellular (“Tandem”) Mee
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced data from the ANCHOR Phase 1...
Mar 16, 2022 04:10 pm ET
Athenex Provides Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
Announces Strategic Pivot to Focus on Cell Therapy Programs Receives FDA Clearance for IND to Expand CD19 CAR-NKT ANCHOR to a Multi-center Study Implementing Significant Cost Reduction Plan Targeting >- Athenex, Inc., (NASDAQ: ATNX), a global...
Mar 14, 2022 08:00 am ET
CORRECTION: Athenex to Provide Corporate and Financial Update for the Fourth Quarter and Full Year 2021, on March 16, 2022
Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a...
Mar 07, 2022 08:00 am ET
Athenex to Provide Corporate and Financial Update for the Fourth Quarter and Full Year 2021, on March 15, 2022
Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a...
Feb 22, 2022 08:00 am ET
Athenex Announces Appointment of Chief Financial Officer
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that Mr. Joe Annoni will join...
Feb 15, 2022 09:00 am ET
Athenex Announces Completion of Sale of Dunkirk Manufacturing Facility
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today the close of the sale of its...
Feb 09, 2022 08:00 am ET
Athenex to Present at the 11th Annual SVB Leerink Global Healthcare Conference
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that Johnson Lau, CEO and Board...
Jan 12, 2022 08:30 am ET
Athenex Announces Agreement with ImmunityBio Regarding Dunkirk Manufacturing Facility
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that it has entered into a...
Dec 29, 2021 06:03 pm ET
SHAREHOLDER ALERT: Robbins LLP is Investigating Athenex, Inc. (ATNX) for Shareholders
Shareholder rights law firm Robbins LLP is investigating Athenex, Inc. (NASDAQ: ATNX) to determine whether certain Athenex officers and directors violated the Securities Exchange Act of 1934 and breached their fiduciary duties to the Company. Athenex is a global clinical stage biopharmaceutical company dedicated to the discovery, d
Dec 13, 2021 07:00 am ET
Athenex to Host a KOL Webinar Today on CAR-NKT Cell Approach to Cancer and Latest Data at the 63rd ASH Annual Meeting
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today it will host a virtual Key...
Nov 30, 2021 08:00 am ET
Athenex to Host Key Opinion Leader Webinar on CAR-NKT Approach to Cancer
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it will host a virtual key...
Nov 29, 2021 08:00 am ET
Athenex Announces UK MHRA Validation of the Marketing Authorization Application for Oral Paclitaxel and Encequidar for Review
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that its Marketing Authorization...
Nov 22, 2021 08:00 am ET
Athenex to Present Subgroup Analysis from Phase 3 Study of Oral Paclitaxel Plus Encequidar (KX-ORAX-001) in Metastatic Breast Cancer at SABCS 2021
Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that an abstract for a subgroup...
Nov 18, 2021 08:00 am ET
Athenex to Present at the Evercore ISI 4th Annual HealthCONx Conference
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that Johnson Lau, CEO and Board...
Nov 09, 2021 08:00 am ET
Athenex Announces Exclusive License Agreement with National Cancer Institute to Utilize T Cell Receptors Targeting Mutated p53, KRAS, and EGFR for the Development of Autologous and Allogeneic Cell The
Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced a licensing agreement with the National...
Nov 04, 2021 09:15 am ET
Athenex Presents Interim Data from ANCHOR Study of KUR-502 (Allogeneic CD19 CAR-NKT Cells) in Relapsed or Refractory Lymphoma and Leukemia at 63rd ASH Annual Meeting and Exposition
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today data from the ANCHOR Phase 1...
Nov 04, 2021 07:00 am ET
Athenex Provides Third Quarter 2021 Corporate and Financial Update
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today provided a corporate and financial update...
Oct 22, 2021 04:05 pm ET
Athenex to Provide Corporate and Financial Update for the Third Quarter 2021, on November 4, 2021
Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a...
Oct 21, 2021 08:00 am ET
Athenex to Provide Corporate and Financial Update for the Third Quarter 2021, on November 5, 2021
Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a...
Oct 18, 2021 08:15 am ET
Athenex and the Center for Cell and Gene Therapy Announce Allowance of Our First U.S. Patent Claims Around CAR-NKT Cell Therapy
Athenex (NASDAQ: ATNX), the leading developer of NKT cell therapy and the Center for Cell and Gene Therapy at Baylor College of Medicine, Texas Children’s Hospital and Houston Methodist Hospital today announced that the U.S. Patent and Trademark...
Oct 12, 2021 09:31 am ET
Thinking about buying stock in Protara Therapeutics, Standard Lithium, Lucid Group, Athenex, or FuelCell Energy?
NEW YORK, Oct. 12, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TARA, SLI, LCID, ATNX, and FCEL.
Oct 11, 2021 08:00 am ET
Athenex Provides Update from FDA Type A Meeting Regarding Oral Paclitaxel + Encequidar in Metastatic Breast Cancer
Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it recently held a Type A meeting...
Sep 27, 2021 08:00 am ET
Athenex Announces Phased European Launch of Klisyri® (tirbanibulin) for the Treatment of Actinic Keratosis
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that its partner, Almirall...
Sep 16, 2021 02:30 am ET
Athenex Presents Data from Oral Paclitaxel + Pembrolizumab Phase 1 Study at ESMO 2021
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today the presentation of data from a...
Sep 15, 2021 08:40 am ET
Thinking about buying stock in GreenSky, Athenex, Cano Health, Oil States International, or Marathon Digital?
NEW YORK, Sept. 15, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GSKY, ATNX, CANO, OIS, and MARA.
Sep 15, 2021 08:00 am ET
Athenex to Present at the Oppenheimer 2021 Fall Healthcare Life Sciences & Med Tech Summit
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that Johnson Lau, CEO and Board...
Aug 05, 2021 07:00 am ET
Athenex Provides Second Quarter 2021 Corporate and Financial Update
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today provided a corporate and financial update...
Jul 26, 2021 07:00 am ET
Athenex Announces Additional Licensing Agreements for Tirbanibulin
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that the Company has entered...
Jul 22, 2021 08:47 am ET
Athenex to Provide Corporate and Financial Update for the Second Quarter 2021 on August 5, 2021
Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a...
Jul 19, 2021 10:51 am ET
Athenex Announces European Commission Approval of Klisyri® (tirbanibulin) for the Topical Treatment of Actinic Keratosis
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that its partner, Almirall...
Jul 06, 2021 07:00 am ET
Athenex Provides Update from FDA Type A Meeting Regarding Oral Paclitaxel Plus Encequidar for the Treatment of Metastatic Breast Cancer
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company held a Type A...
Jun 28, 2021 12:48 pm ET
Lifshitz Law Firm, P.C. Announces Investigations of Athenex, Inc. (NasdaqGS:ATNX), Canoo, Inc. (NasdaqGS: GOEV), Ebix, Inc. (NasdaqGS: EBIX), and Intrusion, Inc. (NasdaqCM: INTZ)
Athenex, Inc. (NasdaqGS: ATNX) Lifshitz Law Firm, P.C. announces that a class action complaint was filed against ATNX alleging ATNX made false and/or misleading statements and/or failed to disclose that: (i) the data included in the Oral...
Jun 07, 2021 02:57 pm ET
SHAREHOLDER ALERT: Robbins LLP is Investigating Athenex, Inc. (ATNX) for Shareholders
Shareholder rights law firm Robbins LLP is investigating Athenex, Inc. (NASDAQ: ATNX) to determine whether certain Athenex officers and directors violated the Securities Exchange Act of 1934 and breached their fiduciary duties to the Company. Athenex is a global clinical stage biopharmaceutical company dedicated to the discovery, d
Jun 04, 2021 09:05 am ET
Athenex Presents Data on Oral Docetaxel and Oral Paclitaxel at ASCO2021 Virtual Scientific Program
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that the Company presented data...
May 21, 2021 09:21 am ET
Athenex Announces Klisyri® (tirbanibulin) Receives Positive CHMP Opinion from the European Medicines Agency (EMA) for the Treatment of Actinic Keratosis of the Face or Scalp
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that its partner, Almirall...
May 17, 2021 07:00 am ET
Athenex, Texas Children’s Cancer Center, and the Center for Cell and Gene Therapy at Baylor College of Medicine Present New Clinical Data on GD2 CAR-NKT Cells in Neuroblastoma at ASGCT Annual Meeting
Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, led by its Orascovery platform, today announced...
May 06, 2021 07:00 am ET
Athenex Provides First Quarter 2021 Corporate and Financial Update
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today provided a corporate and financial update...
May 04, 2021 05:04 pm ET
Athenex to Acquire Kuur Therapeutics to Expand Cell Therapy Development with Off-the-Shelf Engineered CAR-NKT Platform
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, led by its Orascovery platform, today announced...
May 03, 2021 10:00 am ET
DEADLINE ALERT for VLDR, REGI, OTRK, and ATNX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
May 01, 2021 05:37 pm ET
ATNX DEADLINE MONDAY: HAGENS BERMAN, National Trial Attorneys, Alerts Athenex (ATNX) Investors to May 3rd Application Deadline in Securities Class Action, Advises Investors with Losses to Contact the
Hagens Berman urges Athenex, Inc. (NASDAQ: ATNX) investors with significant losses to submit your losses now. Class Period: Aug. 7, 2019 – Feb. 26, 2021 Lead Plaintiff Deadline: May 3, 2021 Visit: www.hbsslaw.com/investor-fraud/atnx  Contact An...
May 01, 2021 09:30 am ET
FINAL DEADLINE ALERT: ROSEN, A LEADING LAW FIRM, Encourages Athenex, Inc. Investors With Losses over $100K to Secure Counsel Before Important Monday Deadline in Securities Class Action – ATNX
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Athenex, Inc. (NASDAQ: ATNX) between August 7, 2019 and February 26, 2021, inclusive (the “Class Period”), of the important May 3, 2021 lead plaintiff...
Apr 30, 2021 09:00 pm ET
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Athenex, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the Western District of New York on behalf of investors that...
Apr 30, 2021 11:00 am ET
ATNX Upcoming Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Athenex, Inc. Shareholders of Class Action and Lead Plaintiff Deadline: May 3, 2021
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Athenex, Inc. ("Athenex" or "the Company") (NASDAQ: ATNX) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Athenex securities between August 7, 2019 and February 26, 2021, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site:
Apr 29, 2021 11:00 am ET
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Athenex, Inc. (ATNX)
The Law Offices of Frank R. Cruz reminds investors of the upcoming May 3, 2021 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Athenex, Inc. (“Athenex” or the “Company”) (NASDAQ:
Apr 28, 2021 10:00 pm ET
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Athenex, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the Western District of New York on behalf of investors that purchased Athenex, Inc. (NASDAQ: ATNX) common stock between August 7, 2019 and February 26, 2021, inclusive (the “Class Period”). Investors have until May 3, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Apr 28, 2021 09:04 pm ET
Athenex, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm
The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Athenex, Inc. (NASDAQ: ATNX) investors that acquired shares between August 7, 2019 and February 26, 2021. Investors have until May 3, 2021 to seek an...
Apr 28, 2021 11:00 am ET
Bronstein, Gewirtz & Grossman, LLC Reminds Athenex, Inc. (ATNX) Shareholders of Class Action and Lead Plaintiff Deadline: May 3, 2021
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Athenex, Inc. ("Athenex" or "the Company") (NASDAQ: ATNX) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Athenex securities between August 7, 2019 and February 26, 2021, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site:
Apr 27, 2021 08:45 pm ET
ATNX BREAKING NOTICE: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Athenex, Inc. Investors with Losses to Secure Counsel Before Important May 3 Deadline in Securities Class Action – ATNX
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Athenex, Inc. (NASDAQ: ATNX) between August 7, 2019 and February 26, 2021, inclusive (the “Class Period”), of the important May 3, 2021 lead plaintiff...
Apr 27, 2021 04:05 pm ET
Athenex to Provide Corporate and Financial Update for the First Quarter 2021 on May 6, 2021
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a...
Apr 27, 2021 04:00 pm ET
IMMINENT SHAREHOLDER DEADLINE: Block & Leviton LLP Has Filed a Lawsuit Against Athenex, Inc. for Securities Fraud; Investors Who Lost Money Should Contact the Firm
Block & Leviton LLP (www.blockleviton.com), a national securities litigation firm, reminds investors that it has filed a class action lawsuit on behalf of shareholders against Athenex, Inc. (NASDAQ: ATNX) and certain of its executives for...
Apr 27, 2021 11:00 am ET
ATNX & OTRK Upcoming Deadlines: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders of Class Actions and Encourages Investors to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Apr 26, 2021 11:45 am ET
ATNX 7-DAY DEADLINE ALERT: HAGENS BERMAN Alerts Athenex (ATNX) Investors to May 3rd Application Deadline in Securities Class Action, Advises Investors with Losses to Contact the Firm Now
Hagens Berman urges Athenex, Inc. (NASDAQ: ATNX) investors with significant losses to submit your losses now. Class Period: Aug. 7, 2019 – Feb. 26, 2021Lead Plaintiff Deadline: May 3, 2021Visit: www.hbsslaw.com/investor-fraud/ATNX Contact An...
Apr 26, 2021 11:30 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Athenex, Inc. (ATNX)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming May 3, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Athenex, Inc. (“Athenex” or the...
Apr 26, 2021 11:00 am ET
DEADLINE ALERT for VLDR, REGI, OTRK, and ATNX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Apr 26, 2021 10:41 am ET
Scott+Scott Attorneys at Law LLP Alerts Investors to Securities Class Action Against Athenex, Inc. (ATNX) and May 3 Deadline
Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, announces the filing of a class action lawsuit against Athenex, Inc. (“Athenex” or the “Company”) (NASDAQ: ATNX) and certain of its officers, alleging violations of federal securities laws. If y
Apr 24, 2021 01:14 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Athenex, Inc., of Class Action Lawsuit and Upcoming Deadline – ATNX
Pomerantz LLP announces that a class action lawsuit has been filed against Athenex, Inc. (“Athenex” or the “Company”) (NASDAQ: ATNX) and certain of its officers.   The class action, filed in the United States District Court for the Western District...
Apr 21, 2021 03:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Velodyne Lidar, Renewable Energy Group, Athenex, and Ontrak and Encourages Investors to Contact the Fir
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Velodyne Lidar, Inc. (NASDAQ: VLDR), Renewable Energy Group, Inc. (NASDAQ:...
Apr 21, 2021 02:48 pm ET
ATNX ALERT: Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against Athenex, Inc. – ATNX
Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Athenex, Inc. (NASDAQ: ATNX) between August 7, 2019 and February 26, 2021, inclusive (the “Class Period”). To join the class action, go to...
Apr 21, 2021 11:00 am ET
DEADLINE ALERT for VLDR, REGI, OTRK, and ATNX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Apr 21, 2021 10:00 am ET
ATNX & OTRK Upcoming Class Actions: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders of Class Actions and Encourages Investors to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Apr 20, 2021 11:00 am ET
DEADLINE ALERT for OTRK, ATNX, LDOS, RRC: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Apr 19, 2021 01:20 pm ET
ATNX 2-WEEK DEADLINE ALERT: HAGENS BERMAN Urges Athenex (ATNX) Investors with Losses to Contact Its Attorneys, Securities Class Action Deadline Approaching
Hagens Berman urges Athenex, Inc. (NASDAQ: ATNX) investors with significant losses to submit your losses now. Class Period: Aug. 7, 2019 – Feb. 26, 2021Lead Plaintiff Deadline: May 3, 2021Visit: www.hbsslaw.com/investor-fraud/ATNXContact An...
Apr 17, 2021 01:45 pm ET
ATNX BREAKING NOTICE: ROSEN, A TOP RANKED LAW FIRM, Encourages Athenex, Inc. Investors with Losses to Secure Counsel Before Important Deadline – ATNX
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Athenex, Inc. (NASDAQ: ATNX) between August 7, 2019 and February 26, 2021, inclusive (the “Class Period”), of the important May 3, 2021 lead plaintiff...
Apr 14, 2021 11:07 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Athenex, Inc., of Class Action Lawsuit and Upcoming Deadline – ATNX
Pomerantz LLP announces that a class action lawsuit has been filed against Athenex, Inc. (“Athenex” or the “Company”) (NASDAQ: ATNX) and certain of its officers.   The class action, filed in the United States District Court for the Western District...
Apr 14, 2021 04:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Renewable Energy Group, Athenex, Ontrak, and Leidos and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Renewable Energy Group, Inc. (NASDAQ: REGI), Athenex, Inc. (NASDAQ: ATNX),...
Apr 14, 2021 11:00 am ET
DEADLINE ALERT for VLDR, REGI, OTRK, and ATNX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Apr 14, 2021 11:00 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Athenex, Inc. (ATNX)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming May 3, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Athenex, Inc. (“Athenex” or the...
Apr 13, 2021 05:35 pm ET
ATNX SHAREHOLDER DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Athenex, Inc.
Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...
Apr 12, 2021 07:14 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Athenex (ATNX) Investors with Losses to Contact Its Attorneys, Securities Class Action Filed
Hagens Berman urges Athenex, Inc. (NASDAQ: ATNX) investors with significant losses to submit your losses now. Class Period:Aug. 7, 2019 – Feb. 26, 2021Lead Plaintiff Deadline:May 3, 2021Visit:www.hbsslaw.com/investor-fraud/ATNXContact An...
Apr 12, 2021 01:00 pm ET
DEADLINE ALERT for OTRK, ATNX, LDOS, RRC: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Apr 12, 2021 10:00 am ET
ATNX & OTRK Class Actions: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders of Class Actions and Encourages Investors to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Apr 10, 2021 03:00 pm ET
ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages Athenex, Inc. Investors to Secure Counsel Before Important May 3 Deadline – ATNX
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Athenex, Inc. (NASDAQ: ATNX) between August 7, 2019 and February 26, 2021, inclusive (the “Class Period”), of the important May 3, 2021 lead plaintiff...
Apr 08, 2021 10:00 am ET
DEADLINE ALERT for VLDR, REGI, OTRK, and ATNX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Apr 07, 2021 05:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Velodyne Lidar, Renewable Energy Group, Athenex, and Ontrak and Encourages Investors to Contact the Fir
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Velodyne Lidar, Inc. (NASDAQ: VLDR), Renewable Energy Group, Inc. (NASDAQ:...
Apr 07, 2021 04:00 pm ET
LAWSUIT FILED: Block & Leviton LLP Has Filed a Lawsuit Against Athenex, Inc. for Securities Fraud; Investors Who Lost Money Should Contact the Firm
Block & Leviton LLP (www.blockleviton.com), a national securities litigation firm, reminds investors that it has filed a class action lawsuit on behalf of shareholders against Athenex, Inc. (NASDAQ: ATNX) and certain of its executives for...
Apr 06, 2021 10:44 pm ET
ATNX SHAREHOLDER DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Athenex, Inc.
Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...
Apr 05, 2021 01:35 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Athenex (ATNX) Investors of Securities Fraud Lawsuit and Application Deadline, Encourages Investors with Losses to Contact Their Attorneys
Hagens Berman urges Athenex, Inc. (NASDAQ: ATNX) investors with significant losses to submit your losses now. Class Period:Aug. 7, 2019 – Feb. 26, 2021Lead Plaintiff Deadline:May 3, 2021Visit:www.hbsslaw.com/investor-fraud/ATNXContact An Attorney...
Apr 03, 2021 04:30 pm ET
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Athenex, Inc. Investors With Losses to Secure Counsel Before Important May 3 Deadline – ATNX
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Athenex, Inc. (NASDAQ: ATNX) between August 7, 2019 and February 26, 2021, inclusive (the “Class Period”), of the important May 3, 2021 lead plaintiff deadline.
Apr 02, 2021 11:30 am ET
DEADLINE ALERT for OTRK, ATNX, LDOS, RRC: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Apr 01, 2021 10:12 pm ET
ATNX INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Athenex, Inc.
Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...
Mar 31, 2021 05:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Infinity Q, Velodyne Lidar, Renewable Energy Group, and Athenex and Encourages Investors to Contact the
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Infinity Q Diversified Alpha Fund (NASDAQ: IQDAX, IQDNX), Velodyne Lidar, Inc....
Mar 31, 2021 12:15 pm ET
ATNX DEADLINE: Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against Athenex, Inc. – ATNX
Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Athenex, Inc. (NASDAQ: ATNX) between August 7, 2019 and February 26, 2021, inclusive (the “Class Period”). To join the class action, go to...
Mar 31, 2021 12:00 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Athenex, Inc. (ATNX)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming May 3, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Athenex, Inc. (“Athenex” or the...
Mar 31, 2021 08:00 am ET
DEADLINE ALERT for VLDR, REGI, OTRK, and ATNX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Mar 29, 2021 12:46 pm ET
Scott+Scott Attorneys at Law LLP Alerts Investors to Securities Class Action Against Athenex, Inc. (ATNX) and May 3 Deadline
Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, announces the filing of a class action lawsuit against Athenex, Inc. (“Athenex” or the “Company”) (NASDAQ: ATNX) and certain of its officers, alleging violations of federal securities laws. If y
Mar 27, 2021 04:45 pm ET
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Athenex, Inc. Investors to Secure Counsel Before Important May 3 Deadline – ATNX
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Athenex, Inc. (NASDAQ: ATNX) between August 7, 2019 and February 26, 2021, inclusive (the “Class Period”), of the important May 3, 2021 lead plaintiff...
Mar 26, 2021 12:30 pm ET
DEADLINE ALERT for OTRK, ATNX, LDOS, RRC: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Mar 24, 2021 06:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Renewable Energy Group, Athenex, Ontrak, and Leidos and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Renewable Energy Group, Inc. (NASDAQ: REGI), Athenex, Inc. (NASDAQ: ATNX),...
Mar 24, 2021 02:10 pm ET
SHAREHOLDER ALERT: Robbins LLP Reminds Shareholders that Athenex, Inc. (ATNX) is Being Sued for Misleading Shareholders
Shareholder rights law firm Robbins LLP reminds shareholders that a purchaser of Athenex, Inc. (NASDAQ: ATNX) filed a class action complaint against the Company and its officers and directors for alleged violations of the Securities Exchange Act of 1934 between August 7, 2019 and February 26, 2021. Athenex is a global clinical stag
Mar 24, 2021 11:00 am ET
DEADLINE ALERT for VLDR, REGI, OTRK, and ATNX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Mar 23, 2021 01:45 pm ET
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Athenex, Inc. (ATNX)
Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Athenex, Inc. (“Athenex” or the “Company”) (NASDAQ: ATNX) in the United States District Court for the Western District of New York on behalf of those who...
Mar 22, 2021 05:09 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds Athenex (ATNX) Investors of Securities Class Action and Encourages Investors with Losses to Contact Its Attorneys
Hagens Berman urges Athenex, Inc. (NASDAQ: ATNX) investors with significant losses to submit your losses now. Class Period: Aug. 7, 2019 – Feb. 26, 2021Lead Plaintiff Deadline: May 3, 2021Visit: www.hbsslaw.com/investor-fraud/ATNX Contact An...
Mar 19, 2021 05:45 pm ET
ROSEN, A TOP RANKED LAW FIRM, Encourages Athenex, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ATNX
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Athenex, Inc. (NASDAQ: ATNX) between August 7, 2019 and February 26, 2021, inclusive (the “Class Period”), of the important May 3, 2021 lead plaintiff...
Mar 19, 2021 01:00 pm ET
DEADLINE ALERT for OTRK, ATNX, LDOS, RRC: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Mar 18, 2021 11:00 am ET
DEADLINE ALERT for VLDR, REGI, OTRK, and ATNX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Mar 18, 2021 08:00 am ET
LAWSUIT FILED: Block & Leviton LLP Has Filed a Lawsuit Against Athenex, Inc. for Securities Fraud; Investors Who Lost Money Should Contact the Firm
Block & Leviton LLP (www.blockleviton.com), a national securities litigation firm, reminds investors that it has filed a class action lawsuit on behalf of shareholders against Athenex, Inc. (NASDAQ: ATNX) and certain of its executives for...
Mar 17, 2021 06:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Infinity Q, Velodyne Lidar, Renewable Energy Group, and Athenex and Encourages Investors to Contact the
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Infinity Q Diversified Alpha Fund (NASDAQ: IQDAX, IQDNX), Velodyne Lidar, Inc....
Mar 16, 2021 03:06 pm ET
ATNX DEADLINE: Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against  Athenex, Inc. – ATNX
Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of   Athenex, Inc. (NASDAQ: ATNX) between August 7, 2019 and February 26, 2021, inclusive (the “Class Period”). To join the class action, go to...
Mar 15, 2021 02:51 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Notifies Athenex (ATNX) Investors of Filing of Securities Fraud Lawsuit, Encourages Investors with Losses to Contact Its Attorneys
Hagens Berman urges Athenex, Inc. (NASDAQ: ATNX) investors with significant losses to submit your losses now. Class Period: Aug. 7, 2019 – Feb. 26, 2021Lead Plaintiff Deadline: May 3, 2021Visit: www.hbsslaw.com/investor-fraud/ATNX Contact An...
Mar 12, 2021 05:22 pm ET
ROSEN, A LEADING LAW FIRM, Encourages Athenex, Inc. Investors with Losses to Secure Counsel Before Important Deadline – ATNX
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Athenex, Inc. (NASDAQ: ATNX) between August 7, 2019 and February 26, 2021, inclusive (the “Class...
Mar 12, 2021 12:30 pm ET
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Athenex, Inc. (ATNX)
Law Offices of Howard G. Smith reminds investors of the upcoming May 3, 2021 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Athenex, Inc. (“Athenex” or the “Company”) (NASDAQ: ATNX) common stock between August 7, 2019 and February 26, 2021, inclusive (the “Class Period”).
Mar 12, 2021 11:30 am ET
DEADLINE ALERT for VLDR, REGI, ATNX, and LDOS: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Mar 10, 2021 08:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Infinity Q, Velodyne Lidar, Renewable Energy Group, and Athenex and Encourages Investors to Contact the
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Infinity Q Diversified Alpha Fund (NASDAQ: IQDAX, IQDNX), Velodyne Lidar, Inc....
Mar 10, 2021 01:00 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Athenex, Inc. (ATNX)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming May 3, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Athenex, Inc. (“Athenex” or the “Company”) (NASDAQ:
Mar 10, 2021 10:00 am ET
Bronstein, Gewirtz & Grossman, LLC Notifies Athenex, Inc. (ATNX) Investors of Class Action and Encourages Shareholders to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Athenex, Inc. ("Athenex" or "the Company") (NASDAQ: ATNX) and certain of its officers, on behalf of shareholders who...
Mar 08, 2021 06:56 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Athenex (ATNX) Investors with Losses to Contact Its Attorneys, Securities Fraud Case Filed
Hagens Berman urges Athenex, Inc. (NASDAQ: ATNX) investors with significant losses to submit your losses now. Class Period: Aug. 7, 2019 – Feb. 26, 2021Lead Plaintiff Deadline: May 3, 2021Visit: www.hbsslaw.com/investor-fraud/ATNX Contact An...
Mar 08, 2021 04:58 pm ET
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Athenex, Inc. Investors to Secure Counsel Before Important Deadline – ATNX
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Athenex, Inc. (NASDAQ: ATNX) between August 7, 2019 and February 26, 2021, inclusive (the “Class...
Mar 08, 2021 12:00 pm ET
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Athenex, Inc. (ATNX) Investors
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise Athenex, Inc. (“Athenex” or the “Company”) (NASDAQ:
Mar 05, 2021 06:54 pm ET
SHAREHOLDER ALERT: Robbins LLP Announces That Athenex, Inc. (ATNX) is Being Sued for Misleading Shareholders
Shareholder rights law firm Robbins LLP announces that a purchaser of Athenex, Inc. (NASDAQ: ATNX) filed a class action complaint against the Company and its officers and directors for alleged violations of the Securities Exchange Act of 1934 between August 7, 2019 and February 26, 2021. Athenex is a global clinical stage biopharmaceutica
Mar 05, 2021 12:49 pm ET
Scott+Scott Attorneys at Law LLP Alerts Investors to Securities Class Action Against Athenex, Inc. (ATNX) and May 3 Deadline
Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, announces the filing of a class action lawsuit against Athenex, Inc. (“Athenex” or the “Company”) (NASDAQ: ATNX) and certain of its...
Mar 05, 2021 11:30 am ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Athenex, Inc. (ATNX) Investors
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Athenex, Inc. (“Athenex” or the “Company”) (NASDAQ: ATNX) securities between August 7, 2019 and February 26, 2021, inclusive (the “Class Period”). Athenex investors have until May 3, 2021 to file a lead plaintiff mo
Mar 05, 2021 11:00 am ET
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Athenex, Inc. (ATNX) Investors
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Athenex, Inc. (“Athenex” or the “Company”) (NASDAQ:
Mar 04, 2021 07:42 pm ET
ATNX BREAKING NEWS: ROSEN, A LEADING LAW FIRM, Encourages Athenex, Inc. Investors to Secure Counsel Before Important Deadline – ATNX
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Athenex, Inc. (NASDAQ: ATNX) between August 7, 2019 and February 26, 2021, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 3, 2021.
Mar 04, 2021 05:17 pm ET
ATNX INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Athenex, Inc.
Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of Athenex, Inc. ("Athenex" or the "Company")...
Mar 04, 2021 03:15 pm ET
Notice of Lead Plaintiff Deadline for Shareholders in the Athenex, Inc. Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP announces that a class action lawsuit has been filed in the Western District of New York on behalf of purchasers of Athenex, Inc. (NASDAQ:ATNX) common stock between August 7, 2019 and February 26, 2021, inclusive (the “Class Period”). The case is captioned Gupta v. Athenex, Inc., No. 21-cv-00337. The Athenex class action lawsuit charges Athenex and certain of its officers with violations of the Securities Exchange Act of 1934.
Mar 04, 2021 01:00 pm ET
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Athenex, Inc. (ATNX) on Behalf of Investors
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Athenex, Inc. (“Athenex” or the “Company”) (NASDAQ:
Mar 04, 2021 08:57 am ET
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athenex, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Athenex, Inc. (“Athenex” or “the Company”) (NASDAQ:
Mar 03, 2021 09:00 pm ET
ATHENEX ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Athenex, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the Western District of New York on behalf of investors that purchased Athenex, Inc. (NASDAQ: ATNX) common stock between August 7, 2019 and February 26, 2021, inclusive (the “Class Period”). Investors have until May 3, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Mar 03, 2021 06:30 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Athenex, Inc. (ATNX) on Behalf of Investors
Law Offices of Howard G. Smith announces an investigation on behalf of Athenex, Inc. (“Athenex” or the “Company”) (NASDAQ: ATNX) investors concerning the Company’s possible violations of federal securities laws.
Mar 03, 2021 05:02 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Athenex (ATNX) Investors to Securities Fraud Investigation and Encourages Investors with Losses to Contact Its Attorneys
Hagens Berman urges Athenex, Inc. (NASDAQ: ATNX) investors with significant losses to submit your losses now. The firm is investigating possible securities law violations and certain investors may have valuable claims. Visit:...
Mar 03, 2021 04:51 pm ET
The Law Offices of Frank R. Cruz Announces Investigation of Athenex, Inc. (ATNX) on Behalf of Investors
The Law Offices of Frank R. Cruz announces an investigation of Athenex, Inc. (“Athenex” or the “Company”) (NASDAQ:
Mar 03, 2021 02:59 pm ET
Athenex Investor Alert: Kaplan Fox Investigates Potential Securities Fraud at Athenex, Inc.
Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Athenex, Inc. (“Athenex” or the “Company”) (NASDAQ: ATNX). On March 1, 2021, Athenex issued a press release reporting its fourth quarter results and...
Mar 03, 2021 02:39 pm ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athenex, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Athenex, Inc. (“Athenex” or “the Company”) (NASDAQ:
Mar 02, 2021 09:38 am ET
SHAREHOLDER ALERT: Labaton Sucharow Investigates Claims On Behalf of Investors of Athenex, Inc. (NASDAQ: ATNX)
Labaton Sucharow, a nationally ranked and award-winning shareholder rights firm, is investigating potential securities violations and breach of fiduciary duty claims against Athenex, Inc. (NASDAQ: ATNX).
Mar 01, 2021 08:29 pm ET
Have You Lost Money Investing In Athenex, Inc. Securities? – Kehoe Law Firm, P.C. Class Action Investigation On Behalf Of ATNX Investors Who Have Suffered Losses Greater Than $50,000
Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Athenex, Inc. (“Athenex” or the “Company”) (NASDAQ: ATNX) to determine whether the Company engaged in securities fraud or other unlawful business...
Mar 01, 2021 11:39 am ET
SHAREHOLDER ALERT: Labaton Sucharow Investigates Claims On Behalf of Investors of Athenex, Inc. (NASDAQ: ATNX)
Labaton Sucharow, a nationally ranked and award-winning shareholder rights firm, is investigating potential securities violations and breach of fiduciary duty claims against Athenex, Inc. (NASDAQ: ATNX).
Mar 01, 2021 07:05 am ET
Athenex Provides Fourth Quarter and Full Year 2020 Corporate and Financial Update
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today provided a corporate and financial update...
Mar 01, 2021 07:00 am ET
Athenex Receives FDA Complete Response Letter for Oral Paclitaxel Plus Encequidar for the Treatment of Metastatic Breast Cancer
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the U.S. Food and Drug...
Feb 22, 2021 07:00 am ET
Athenex to Provide a Corporate and Financial Update for the Fourth Quarter and Full Year 2020 on March 1, 2021
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a...
Feb 18, 2021 07:55 am ET
Athenex Announces U.S. Launch of Klisyri® and Licensing of Additional Territories for Tirbanibulin
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced that today marks the U.S. launch of...
Feb 18, 2021 06:55 am ET
Almirall U.S. Launches Klisyri® (tirbanibulin), a New, Innovative Topical Treatment for Actinic Keratosis
EXTON, Pa., Feb. 18, 2021 /PRNewswire/ -- Almirall, S.A. (BME:ALM), a global biopharmaceutical company focused on skin health, announced today the U.S. commercial launch of Klisyri® (tirbanibulin), developed for the topical treatment of actinic keratosis (AK) of the face and scalp. Klisyri® was approved by the U.S. Food and Drug Administration (FDA) in December 2020 and is now commercially available.
Feb 11, 2021 07:00 am ET
Athenex Announces New England Journal of Medicine Publication of Phase III Data on the Efficacy and Safety of Klisyri® (tirbanibulin)
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that the New England Journal of...
Feb 11, 2021 06:00 am ET
Almirall announces New England Journal of Medicine publication of Phase III data demonstrating efficacy and safety of Klisyri® (tirbanibulin)
EXTON, Pa., Feb. 11, 2021 /PRNewswire/ -- Almirall, S.A. (BME:ALM), a global biopharmaceutical company focused on skin health, announced today that the New England Journal of Medicine (NEJM) has published the results from the pivotal Phase III trials of Klisyri® (tirbanibulin) ointment for actinic keratosis. The two double-blind, vehicle-controlled, randomized, parallel-group, multi-center trials (KX01-AK-003 and KX01-AK-004), are one of the largest Phase III clinical study programs ever conducted for a topical AK treatment.
Jan 25, 2021 04:05 pm ET
CEO Dr. Johnson Lau Recuperating from COVID at Home
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that its CEO and Board Chairman,...
Jan 08, 2021 04:05 pm ET
CEO Dr. Johnson Lau Contracts COVID-19
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced that its CEO and Board Chairman, Dr....
Jan 05, 2021 04:30 pm ET
Athenex to Present at the 39th Annual J.P. Morgan Healthcare Conference
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced that it will participate in the 39th...
Dec 15, 2020 07:00 am ET
Athenex Announces FDA Approval of Klisyri® (Tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the U.S. Food and Drug...
Dec 15, 2020 06:00 am ET
Almirall announces FDA approval of Klisyri® (tirbanibulin), a new innovative topical treatment for actinic keratosis
EXTON, Pa., Dec. 15, 2020 /PRNewswire/ -- Almirall, S.A. (BME:ALM), a global biopharmaceutical company focused on skin health, announced today that Klisyri® (tirbanibulin) has been approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of actinic keratosis (AK) of the face or scalp. Klisyri® (tirbanibulin) will be launched in the US during the first quarter of 2021.
Dec 09, 2020 08:38 am ET
Athenex Presents Updated Phase 3 Data on Survival and Tolerability Associated with Oral Paclitaxel and Encequidar in Patients with Metastatic Breast Cancer
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today the presentation of updated...
Dec 02, 2020 08:00 am ET
Athenex Pharmaceutical Division and Ingenus Pharmaceuticals Announce Availability of Liquid, Ready to Dilute Cyclophosphamide
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that its subsidiary, Athenex...
Nov 17, 2020 08:05 am ET
Athenex Announces Data on Oral Paclitaxel and Encequidar to be Presented at the 2020 San Antonio Breast Cancer Symposium (SABCS)
Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that oral paclitaxel and...
Nov 05, 2020 07:00 am ET
Athenex, Inc. Reports Third Quarter Ended September 30, 2020 Financial Results and Provides Corporate Update
Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced its financial results and...
Oct 22, 2020 07:00 am ET
Athenex, Inc. to Report Third Quarter 2020 Earnings Results on November 5, 2020
Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it will release third quarter...
Oct 12, 2020 04:05 pm ET
Axis Therapeutics Announces Research Collaboration with PharmaEssentia for Development of TCR-T Cell Therapy in Taiwan
Axis Therapeutics Limited, a joint venture between Athenex, Inc. (NASDAQ: ATNX) and Xiangxue Life Sciences Limited (“XLifeSc”), focused on the research, development, and commercialization of T cell immunotherapy, today announced that it has entered...
Sep 23, 2020 07:00 am ET
Athenex Announces FDA Allowance of IND Application for TCRT-ESO-A2, a TCR-T Cell Therapy
Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the U.S. Food and Drug...
Sep 10, 2020 07:00 am ET
Athenex, Inc. Announces Pricing of $110 Million Public Offering of Common Stock
Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced the pricing of a public offering of 10,000,000 shares of...
Sep 08, 2020 04:01 pm ET
Athenex, Inc. Announces Proposed Public Offering of Common Stock
Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced that it intends to offer and sell, subject to market...
Sep 08, 2020 07:00 am ET
Quantum Leap Healthcare Collaborative and Athenex Announce the Selection of Oral Paclitaxel plus Encequidar in Combination with dostarlimab, an anti-PD-1, in the I-SPY 2 TRIAL targeting Stage 2/3 HER2
Quantum Leap Healthcare Collaborative (Quantum Leap) and Athenex, Inc. (Nasdaq: ATNX) announce the launch of two new study arms of the I-SPY 2 TRIAL to evaluate Athenex’s combination of oral paclitaxel plus encequidar with GSK’s dostarlimab, an...
Sep 01, 2020 07:00 am ET
Athenex Announces FDA Acceptance for Filing of U.S. NDA for Oral Paclitaxel and Encequidar in Metastatic Breast Cancer with Priority Review
Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the U.S. Food and Drug...
Aug 06, 2020 07:00 am ET
Athenex Announces $50 Million Revenue Interest Financing with Sagard Healthcare Royalty Partners
Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it has entered into a $50...
Aug 06, 2020 07:00 am ET
Athenex, Inc. Reports Second Quarter Ended June 30, 2020 Financial Results and Provides Corporate Update
Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced its financial results and business...
Aug 04, 2020 09:30 am ET
Biopharmaceutical Leader Robert J. Spiegel, MD, FACP Appointed to the Athenex Board of Directors
Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the appointment of Robert J....
Jul 27, 2020 07:00 am ET
Athenex, Inc. to Report Second Quarter 2020 Earnings Results on August 6, 2020
Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it will release second...
Jun 23, 2020 07:00 am ET
Athenex Appoints Teresa Bair, Esq. as Executive Officer and General Counsel
Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the promotion of Teresa Bair, Esq....
Jun 22, 2020 08:00 am ET
Athenex Announces $225 Million Loan Agreement with Oaktree
Athenex, Inc. (“Athenex” or the “Company”) (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that...
Jun 13, 2020 10:00 am ET
Athenex Oncology launches Facing MBC Together campaign to address isolation for people living with metastatic breast cancer
BUFFALO, N.Y. and CHICAGO, June 13, 2020 /PRNewswire/ -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer, today announced that Athenex Oncology, a U.S. based division of Athenex, launched Facing MBC Together – a public education and patient support campaign that addresses isolation for people living with metastatic breast cancer (MBC). In addition to providing a unique digital resource that enables the provision of practical and emotional support to individuals with
Jun 08, 2020 06:19 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Athenex, Inc. - ATNX
Pomerantz LLP is investigating claims on behalf of investors of Athenex, Inc. (“Athenex” or the “Company”) (NASDAQ: ATNX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The...
Jun 03, 2020 04:50 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Athenex, Inc. - ATNX
Pomerantz LLP is investigating claims on behalf of investors of Athenex, Inc. (“Athenex” or the “Company”) (NASDAQ: ATNX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The...
May 29, 2020 08:00 am ET
Athenex Presents Interim Data from Oral Paclitaxel Phase II Study in Cutaneous Angiosarcoma at ASCO20 Virtual Scientific Program
Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer, today presented interim data from an ongoing Phase II clinical trial in...
May 27, 2020 08:40 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Athenex, Inc. - ATNX
Pomerantz LLP is investigating claims on behalf of investors of  Athenex, Inc. (“Athenex” or the “Company”) (NASDAQ: ATNX).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The...
May 19, 2020 09:05 am ET
Athenex Announces Participation in the 2020 RBC Capital Markets Global Healthcare Virtual Conference
Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that management will participate...
May 07, 2020 06:47 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Athenex, Inc. – ATNX
Pomerantz LLP is investigating claims on behalf of investors of Athenex, Inc. (“Athenex” or the “Company”) (NASDAQ: ATNX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The...
May 07, 2020 07:00 am ET
Athenex, Inc. Reports First Quarter Ended March 31, 2020 Financial Results and Provides Corporate Update
Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced its financial results and business...
Apr 29, 2020 01:54 pm ET
Athenex Announces Acceptance of Oral Paclitaxel Phase II Study in Angiosarcoma Abstract at ASCO20 Virtual Scientific Program
Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that an abstract for its ongoing...
Apr 23, 2020 08:00 am ET
Athenex, Inc. to Report First Quarter 2020 Earnings Results on May 7, 2020
Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it will release first quarter...
Apr 09, 2020 07:00 am ET
Athenex Provides an Update on Oral Paclitaxel FDA Meeting
Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it recently participated in a...
Mar 13, 2020 08:10 am ET
Athenex Provides a Corporate Update
Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today provides an update on the Company’s...
Mar 09, 2020 07:00 am ET
Athenex Announces FDA Acceptance for Filing of U.S. NDA for Tirbanibulin Ointment in Actinic Keratosis
Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that the U.S. Food and Drug...
Mar 02, 2020 10:19 am ET
Athenex’s Partner Almirall Announces EMA Acceptance for Filing of Marketing Authorization Application (MAA) for Tirbanibulin Ointment in Actinic Keratosis
Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, provided an update today that its partner,...
Feb 27, 2020 07:00 am ET
Athenex, Inc. Reports Fourth Quarter and Year Ended December 31, 2019 Financial Results and Provides Corporate Update
Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced its financial results and business...
Feb 25, 2020 08:00 am ET
Athenex Announces Participation at the Cowen 40th Annual Health Care Conference
Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer, today announced that management will present at the Cowen 40th Annual...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.